Navigation Links
Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
Date:12/7/2007

REDWOOD CITY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from eight studies of the company's Oncotype DX(R) breast cancer test are scheduled to be presented at the 30th Annual San Antonio Breast Cancer Symposium, taking place December 13-16, 2007. Oncotype DX is a multi-gene expression test that physicians use to predict the likelihood of recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients.

Following are details for each embargoed session (all times are Central Standard Time):

Thursday, Dec. 13, 2007, 9:15 to 9:30 a.m.

Abstract #10

Late-Breaking oral presentation: "Prognostic and predictive value of the

21-gene Recurrence Score assay in postmenopausal, node-positive, ER

positive breast cancer.

"Presenter: Kathy S. Albain, M.D.

Thursday, Dec. 13, 2007, 5 to 7 p.m.

Abstract #1043

Poster presentation: Recurrence Score by Oncotype DX evaluated on the

primary breast tumor predicts the 2-year survival after first relapse.

Presenter: Giampaolo Bianchini, M.D.

Abstract #1092

Poster presentation: "Prospective multi-center study of the impact of the

21-gene Recurrence Score assay on patient satisfaction, anxiety and

decisional conflict for adjuvant breast cancer treatment

selection.

"Presenter: Patricia B. Mumby, Ph.D.

Friday, Dec. 14, 7 to 9 a.m.

Abstract #2061

Poster presentation: "A retrospective analysis of the impact of Oncotype

DX low Recurrence Score results on treatment decisions in a single

academic breast cancer center.

"Presenter: Hongmei Liang, M.D., Ph.D.

Friday, Dec. 14, 5 to 7 p.m.

Abstract #3028

Poster presentation: "Gene expression by standardized quantitative RT-PCR

in the special histologic subtypes of estrogen receptor positive invasive

breast cancer.

"Presenter: Frederick L. Baehner, M.D.

Abstract #3082

Poster presentation: "Evaluation of practice patterns in the treatment of

node-negative, hormone-receptor positive breast cancer patients with the

use of the Oncotype DX assay at the University of Pennsylvania.

"Presenter: Christopher Erb, M.D., Ph.D.

Saturday, Dec. 15, 4 to 4:15 p.m.

Abstract #63

Oral presentation: "Prognostic utility of the 21-gene assay

compared with Adjuvant! in hormone receptor (HR) positive operable breast

cancer with 0-3 positive axillary nodes treated with adjuvant

chemohormonal therapy (CHT): an analysis of intergroup trial

E2197.

"Presenter: Lori J. Goldstein, M.D.

Saturday, Dec. 15, 5 to 7 p.m.

Abstract #5029

Poster presentation: "Estrogen receptor and breast cancer survival in a

Kaiser Permanente population-based study: comparison of quantitative

reverse transcriptase polymerase chain reaction and

immunohistochemistry.

"Presenter: Laurel A. Habel, M.D.

About Oncotype DX(R)

Oncotype DX is the first diagnostic multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of breast cancer survival and the likelihood of chemotherapy benefit. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 3,300 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, nearly 7,000 physicians have ordered more than 40,000 tests, and health plans covering over 50 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. The American Society of Clinical Oncologists (ASCO) recommends the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test service, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

NOTE: Genomic Health, the Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
9. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
10. Tone Deafness Explained, from the Harvard Health Letter
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... The International Association of Eating Disorders Professionals ... the field of eating disorders, announces the opening of early registration for the ... at the Omni Resort at ChampionsGate. , The annual iaedp™ Symposium ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
Breaking Medicine News(10 mins):